Sodium–glucose cotransporter 2 (SGLT2) inhibitors and GLP-1 receptor agonists may benefit both glycemic control and renal protection in patients with T2DM and MAFLD/NAFLD [35,36]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.